ReviewFrontiers in genetics2022
New Hope for Genome Editing in Cultivated Grasses: CRISPR Variants and Application.
Review in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Genome-Wide Identification of Ovarian Tumor Proteases Gene Family and Knockout ofPlants (Basel, Switzerland) · 2026Article
- CRISPR/Cas system-mediated transgene-free or DNA-free genome editing in plants.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2025Review
- Multi-Omics Approaches Against Abiotic and Biotic Stress-A Review.Plants (Basel, Switzerland) · 2025Review
- Advancements in Plant Gene Editing Technology: From Construct Design to Enhanced Transformation Efficiency.Biotechnology journal · 2024Review
- Rice Promoter Editing: An Efficient Genetic Improvement Strategy.Rice (New York, N.Y.) · 2024Review
- Leveraging the sugarcane CRISPR/Cas9 technique for genetic improvement of non-cultivated grasses.Frontiers in plant science · 2024Review
- Next-generation CRISPR gene-drive systems using Cas12a nuclease.Nature communications · 2023Article
- CRISPR-Cas System, a Possible "Savior" of Rice Threatened by Climate Change: An Updated Review.Rice (New York, N.Y.) · 2023Review
- Structural transitions upon guide RNA binding and their importance in Cas12g-mediated RNA cleavage.PLoS genetics · 2023Article
- CRISPR/Cas9 genome editing in wheat: enhancing quality and productivity for global food security-a review.Functional & integrative genomics · 2023Review
- Phenotypic and genetic characterization of anFrontiers in plant science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) mediated genome editing, crop improvement has progressed significantly in recent years. In this genome editing tool, CRISPR-associated Cas nucleases are restricted to their target of DNA by their preferred protospacer adjacent motifs (PAMs). A number of CRISPR-Cas variants have been developed e.g. CRISPR-Cas9, -Cas12a and -Cas12b, with different PAM requirements. In this mini-review, we briefly explain the components of the CRISPR-based genome editing tool for crop improvement. Moreover, we intend to highlight the information on the latest development and breakthrough in CRISPR technology, with a focus on a comparison of major variants (CRISPR-Cas9, -Cas12a, and -Cas12b) to the newly developed CRISPR-SpRY that have nearly PAM-less genome editing ability. Additionally, we briefly explain the application of CRISPR technology in the improvement of cultivated grasses with regard to biotic and abiotic stress tolerance as well as improving the quality and yield.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.